The association between early‐onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple‐negative breast cancer patients and some novel autophagy‐related polymorphisms in their genomic DNA: a real‐world study

Binliang Liu(Central South University), Lixi Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Tao An(Kunming Institute of Botany), Zongbi Yi(Wuhan University), Chunxiao Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuhui Zhang(Xuzhou Medical College), Yanfeng Wang(Wuhan University), Meiying Li(Jilin University), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoying Sun(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cancer Communications
December 1, 2018
10.1186/s40880-018-0343-7
Cited by 24

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724